BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16868670)

  • 1. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
    Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
    Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
    J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.
    Alvarez L; RicOs C; Peris P; GuaNabens N; Monegal A; Pons F; Ballesta AM
    Bone; 2000 Jun; 26(6):571-6. PubMed ID: 10831927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
    Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
    J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical markers of bone turnover in Paget's disease of bone.
    Delmas PD
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.
    Pons F; Alvarez L; Peris P; Guañabens N; Vidal-Sicart S; Monegal A; Pavía J; Ballesta AM; Muños-Gómez J; Herranz R
    Nucl Med Commun; 1999 Jun; 20(6):525-8. PubMed ID: 10451864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
    Muschitz C; Feichtinger X; Haschka J; Kocijan R
    Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone.
    Bonnin MR; Moragues C; Nolla JM; Lirón FJ; Roig-Escofet D; Navarro MA
    Clin Chem Lab Med; 1998 Jan; 36(1):53-5. PubMed ID: 9594087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.